Keynote 495

Trial description
Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer 
Contact name
Dr Gary Doherty
Trial start date
Tuesday, April 16, 2019
Trial end date
Sunday, May 31, 2020
Trial tumour type
Lung
Show on Radiotherapy
No